Influence of respiratory disease experiences on COVID-19 vaccine acceptance: a study from Southeastern Louisiana

呼吸系统疾病经历对新冠疫苗接种率的影响:一项来自路易斯安那州东南部的研究

阅读:1

Abstract

INTRODUCTION: Respiratory diseases, including influenza (flu) and respiratory syncytial virus, continue to be major health concerns globally. The onset of COVID-19 further compounded these issues, making it important to examine public attitudes toward vaccination and understanding of respiratory diseases. This study explores factors influencing decisions to receive the latest COVID-19 vaccine, focusing specifically on the role of prior respiratory illness diagnosis. METHODS: A follow-up survey among 299 participants from Southeastern Louisiana across 10 healthcare facilities was administered via phone and the Qualtrics platform, gathering information about the likelihood of receiving the latest COVID-19 vaccine. Quantitative data were analyzed using log-binomial and Poisson regression models to assess relationships between respiratory illness history and COVID-19 vaccine acceptance. RESULTS: Nearly half (47%) of the participants reported a history of respiratory illness. Individuals with prior respiratory diagnosis were more likely to accept the latest COVID-19 vaccine (62%) than those without (41%) (RR: 1.79, 95% CI: 1.26-2.56). In fully adjusted models, accounting for age, prior vaccine hesitancy, and comorbidities, influenza vaccine acceptance (RR: 1.87, 95% CI: 1.06-3.28) was associated with greater likelihood of receiving the latest COVID-19 vaccine. Key barriers to vaccination, including concerns about side effects and distrust in vaccine efficacy were identified. DISCUSSION: Participants with respiratory illnesses and those with positive vaccination histories, particularly regarding influenza, showed a higher likelihood of accepting the latest COVID-19 vaccines. However, significant obstacles to vaccine uptake persist. Tailored public health efforts that address these concerns are crucial to improving vaccine rates, particularly among hesitant groups.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。